IP Library Granted Patent US 8,530,636
Granted Patent B2
US 8,530,636 · App. 12/437,279 · Granted Sep 10, 2013

Method for regulating protein function in cells in vivo using synthetic small molecules

Inventors: Thomas J. Wandless (Menlo Park, CA); Laura A. Banaszynski (New York, NY); Mark A. Sellmyer (Stanford, CA); Christopher H. Contag (Stanford, CA); Steven H. Thorne (Pittsburg, PA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,530,636
App. No.
12/437,279
Granted
Sep 10, 2013
Kind
B2
Abstract

Methods and compositions for the rapid and reversible destabilizing of specific proteins in vivo using cell-permeable, synthetic molecules are described.

Claims (9)

1. An in vivo conditional protein stability system, comprising:

a nucleic acid sequence encoding a fusion protein that comprises a secreted protein selected from TNF-α and IL-2 fused to a single-polypeptide chain, ligand-dependent, stability-affecting protein derived from a naturally-occurring ligand binding protein and is a variant FKBP having F36V and L106P amino acid substitutions, and

a ligand that binds to the stability-affecting protein to modulate stability of the stability-affecting protein, wherein the ligand is Shield1,

wherein upon introduction of the nucleic acid sequence to a eukaryotic cell the fusion protein is expressed and the stability of the fusion protein can be modulated by administering the ligand to the eukaryotic cell.

2. The system of claim 1 , wherein the eukaryotic cells are stably transformed with the nucleic acid.

3. The system of claim 2 , wherein the stably transformed eukaryotic cells are implanted in an animal.

4. The system of claim 1 , wherein the nucleic acid sequence is in a viral vector.

5. The system of claim 4 , wherein the viral vector is a vaccinia virus.

6. The system of claim 4 , wherein the administering the ligand to the cells is by injecting the ligand into an animal intraperitoneally or intravenously.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2018
From: WANDLESS, THOMAS J.; BANASZYNSKI, LAURA A.; SELLMYER, MARK A.; CONTAG, CHRISTOPHER H.; THORNE, STEVEN H.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 046871/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2010
From: WANDLESS, THOMAS J.; BANASZYNSKI, LAURA A.; SELLMYER, MARK A.; CONTAG, CHRISTOPHER H.; THORNE, STEVEN H.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 025244/0199 →
CONFIRMATORY LICENSE Recorded Sep 1, 2009
From: STANFORD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023174/0399 →
Continuity (2)
Provisional Application 61051303 · May 7, 2008
Related Publication 20100034777A1 · Feb 11, 2010